Millions of people around the world are getting affected by this disease and currently there are only five medications approved by the FDA for treating it. However these drugs only alleviate its symptoms and does not treat the disease.
A team of researchers at Midwestern University has discovered a new drug called IRL-1620 that offers new hope in treating the disease itself. IRL-1620 binds to endothelin B receptors that are important for brain development. By stimulation, these receptors can help to protect the nervous system.
Dr.Seema Briyal said, "We used the novel approach of stimulating the endothelin B receptors by intravenous injection of IRL-1620 to prevent and repair the damage to the brain caused by Alzheimer's disease."
Rats with Alzheimer's disease show an impaired learning and memory capacity as oxidative stress increases. The study showed that IRL-1620 reversed those effects, and intravenous injection with the drug improved memory by 50 to 60 percent and reduced oxidative stress by 45 to 50 percent.
"We also found that treatment with IRL-1620 enhanced certain recovery processes within the AD-damaged brain, resulting in more new blood vessels and neuronal cells. This indicates reparative processes occurring in the damaged brain."
According to Briyal and her team, this is the first study to demonstrate that intravaneously injecting IRL-1620 can reverse the neurological effects of Alzheimer's disease by stimulating the endothelin B receptors in rats. This research offers great hope for those suffering from Alzheimer's disease and their families as currently there is no cure for the debilitating disease.